Showing results (41-50 of 154) with videos related to
Sort By:
Pageof 16
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 19, 2009
Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humansYongchuan Gu, Graham J Atwell, William R WilsonChemical Research in Toxicology|November 18, 2003
Enhanced conversion of DNA radical damage to double strand breaks by 1,2,4-benzotriazine 1,4-dioxides linked to a DNA binder compared to tirapazamineRobert F Anderson, Tracy A Harris, Michael P Hay, et al.Journal of the American Chemical Society|January 5, 2006
Potentiation of the cytotoxicity of the anticancer agent tirapazamine by benzotriazine N-oxides: the role of redox equilibriaRobert F Anderson, Sujata S Shinde, Michael P Hay, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2010
Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumorsKevin O Hicks, Bronwyn G Siim, Jagdish K Jaiswal, et al.British Journal of Cancer|April 13, 2016
Hypoxia-activated prodrugs: paths forward in the era of personalised medicineFrancis W Hunter, Bradly G Wouters, William R WilsonInternational Journal of Hematologic Oncology|February 4, 2014
Targeting hypoxia in the leukemia microenvironmentJuliana Benito, Zhihong Zeng, Marina Konopleva, et al.Neoplasia (New York, N.Y.)|December 29, 2018
An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander EffectCho Rong Hong, William R Wilson, Kevin O HicksJournal of Medicinal Chemistry|December 19, 2017
Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole AlkylsulfonamidesMuriel Bonnet, Cho Rong Hong, Way Wua Wong, et al.Frontiers in Pharmacology|August 30, 2017
Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in MiceYongchuan Gu, Tony T-A Chang, Jingli Wang, et al.The Laryngoscope|August 2, 2002
Intralesional cidofovir therapy for laryngeal papilloma in an adult cohortSteven Bielamowicz, Vicente Villagomez, Sheila V Stager, et al.Pageof 16